Correspondence on ‘Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Open Access
- 28 May 2021
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (10), e158
- https://doi.org/10.1136/annrheumdis-2021-220496
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic reviewClinical Rheumatology, 2021
- Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitisRheumatology, 2021
- Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registryAnnals Of The Rheumatic Diseases, 2021
- SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic diseaseAnnals Of The Rheumatic Diseases, 2021
- Mild COVID-19 in ANCA-associated vasculitis treated with rituximabAnnals Of The Rheumatic Diseases, 2020
- Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?European Journal of Cancer, 2020
- 346. FACTORS INFLUENCING B CELL REPOPULATION AFTER REMISSION INDUCTION WITH RITUXIMAB IN NEWLY DIAGNOSED, TREATMENT–NAÏVE PATIENTS WITH ANCA-ASSOCIATED VASCULITISRheumatology, 2019
- B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patientsArthritis Research & Therapy, 2017
- Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patientsClinical and Experimental Immunology, 2014
- Impact of rituximab trials on the treatment of ANCA-associated vasculitisNephrology Dialysis Transplantation, 2013